Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
Clinical trial NCT05232864 · TERMINATED
Trial details
- NCT number
- NCT05232864
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-22
- Primary completion
- 2023-08-23
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.